Skip to main content
. Author manuscript; available in PMC: 2009 May 5.
Published in final edited form as: Ann Neurol. 2007 May;61(5):435–445. doi: 10.1002/ana.21154

Table 4.

Distribution of TDP-43 Immunoreactivity

Initial series
 Confirmation series
HpScl/pure (n=8) HpScl/other (n=5) HpScl/AD (n=33) AD (n=9) AD (n=19)
TDP-43 immunoreactivity score (median, 25%-tile, 75%-tile) and percent affected
    Dentate fascia 1 (1, 1)
100%		 0.5 (0.5, 1)
100%		 1 (1, 1)
100%		 1 (0.5, 1)
100%		 1 (0.5, 1)
100%
    Entorhinal cortex 1 (1, 1)
100%		 1 (0.9, 1)
100%		 1 (1, 1)
100%		 1 (0.9, 1)
100%		 1 (0.6, 1)
100%
    Occipitotemporal cortex 0.5 (0.2, 0.5)
75%		 0.5 (0, 0.5)
60%		 0.5 (0.5, 1)
94%		 0.5 (0, 0.5)
56%		 0.5 (0, 0.5)
63%
    Inferior temporal cortex 0 (0, 0)
13%		 0 (0, 0)
0%		 0 (0, 0.5)
44%		 0 (0, 0)
11%		 0 (0, 0)
21%
    Cingulate gyrus nd nd 0.5 (0, 1)
64%		 0 (0, 0.4)
29%		 nd
    Amygdala nd nd 1 (1, 1)
100%		 1 (1, 1)
100%		 nd
    Nucleus accumbens nd nd 0.5 (0.5, 1)
79%		 0.5 (0, 0.6)
60%		 nd
    Midfrontal gyrus nd nd 0 (0, 0)
13%		 0 (0, 0)
0%		 nd
Number of cases with NII 2 0 5 1 1
TDP-43 type (diffuse:limbic) 0:8 0:5 13:20 1:8 4:15

nd = not done